Faculty profile

David Lebrun

ResearcherPathology and Molecular MedicineQueen's University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Queen's University directory, so their courses and email address may be missing. Find their university profile.

David Lebrun

Researcher

Pathology and Molecular Medicine

Health Sciences

Queen's University

Kingston, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
4 publications in the last five years, latest in 2025.
Principal investigator on 1 research grant (1 CIHR), most recently in 2015.
Supervised 1 trainee who won CIHR awards, most recently in 2009.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Chromatin Gene Transcription Hematopoiesis Leukemia Oncogenes Protein-Protein Interactions Structural Biology

Latest papers

Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
Cancer research · 2025
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
EBioMedicine · 2024
Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.
British journal of haematology · 2024

All 8 publications

Latest funding

Elucidating the mechanisms and reverting the hematopoietic consequences of target gene deregulation by the oncogenic transcription factor E2A-PBX1
CIHR · 2015 · Nominated PI
$100,000
Investigating the impact of E2A-PBX1 on B-cell development.
CIHR · 2009 · Supervisor
$105,000
The Terry Fox Foundation Training Program in Transdiciplinary Cancer Research at CIHR
CIHR · 2008 · Co-investigator
$1,650,000

All 4 grants and awards

8 publications.

Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.

Laight BJ, Harper D, Dmytryk N, Zhang CS, Shi C, Garven A, Nauman RW, Kment J, Alotaibi F, Shapovalov I, Hoskin V, Gao Y, Mewburn J, Vlasschaert C, Wang A, Simonetti J, LeBrun D, Tyryshkin K, Berman DM, Simpson AL, Graham CH, Craig AW, Basta S, Koti M, Greer PA

Cancer research2025

DOI: 10.1158/0008-5472.can-24-3686 PMID: 40299778

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

MacManus MP, Seymour JF, Tsang H, Fisher R, Keane C, Sabdia MB, Law SC, Gunawardana J, Nath K, Kazakoff SH, Marques-Piubelli ML, Duenas DE, Green MR, Roos D, O'Brien P, McCann A, Tsang R, Davis S, Christie D, Cheah C, Amanuel B, Cochrane T, Butler J, Johnston A, Shanavas M, Li L, Vajdic C, Kridel R, Shelton V, Hershenfield S, Baetz T, Lebrun D, Johnson N, Brodtkorb M, Ludvigsen M, d'Amore F, Thompson ER, Blombery P, Gandhi MK, Tobin JWD

EBioMedicine2024

DOI: 10.1016/j.ebiom.2024.105468 PMID: 39631145

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.

Hershenfeld SA, Tobin JWD, Shelton V, Calvente L, Lajkosz K, Liu T, Brodtkorb M, d'Amore FA, Ludvigsen M, Baetz T, LeBrun D, Johnson N, Crump M, Hong M, Kuruvilla J, Tremblay-LeMay R, MacManus M, Tsang R, Hodgson DC, Gandhi MK, Kridel R

British journal of haematology2024

DOI: 10.1111/bjh.19698 PMID: 39112220

Identification of genetic subtypes in follicular lymphoma.

Shelton V, Detroja R, Liu T, Isaev K, Silva A, Passerini V, Bakhtiari M, Calvente L, Hong M, He MY, Modi S, Hershenfeld SA, Ludvigsen M, Madsen C, Hamilton-Dutoit S, d'Amore FA, Brodtkorb M, Johnson NA, Baetz T, LeBrun D, Tobin JWD, Gandhi MK, Mungall AJ, Xu W, Ben-Neriah S, Steidl C, Delabie J, Tremblay-LeMay R, Jegede O, Weigert O, Kahl B, Evens AM, Kridel R

Blood cancer journal2024

DOI: 10.1038/s41408-024-01111-w PMID: 39112453

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Bosch M, Akhter A, Chen BE, Mansoor A, Lebrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA

Haematologica2018

DOI: 10.3324/haematol.2017.179309 PMID: 29097500

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*

Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, LeBrun D, Meyer RM, Sehn LH, Soulières D

Leukemia and Lymphoma201727 citations

DOI: 10.1080/10428194.2017.1312379

Primary cardiac lymphoma: molecular cytogenetic characterization of a rare entity.

Schell AJ, Xu Y, Baetz T, Harrison K, Ropchan G, LeBrun D, Feilotter H

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology2009

DOI: 10.1016/j.carpath.2008.01.002 PMID: 18402841

Predicting outcome in follicular lymphoma by using interactive gene pairs.

LeBrun D, Baetz T, Foster C, Farmer P, Sidhu R, Guo H, Harrison K, Somogyi R, Greller LD, Feilotter H

Clinical cancer research : an official journal of the American Association for Cancer Research2008First author

DOI: 10.1158/1078-0432.ccr-07-1720 PMID: 18223222

Something wrong or missing on this profile? Suggest a correction

David Lebrun

Research

Latest papers

Latest funding

Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy.

Identification of genetic subtypes in follicular lymphoma.

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study*

Primary cardiac lymphoma: molecular cytogenetic characterization of a rare entity.

Predicting outcome in follicular lymphoma by using interactive gene pairs.

Elucidating the mechanisms and reverting the hematopoietic consequences of target gene deregulation by the oncogenic transcription factor E2A-PBX1

Investigating the impact of E2A-PBX1 on B-cell development.

The Terry Fox Foundation Training Program in Transdiciplinary Cancer Research at CIHR

The Terry Fox Foundation Strategic Health Research Training Program in Molecular Pathology of Cancer at CIHR

Frequent collaborators

Robert Kridel

John Kuruvilla

Nathalie Johnson

Madhuri Koti

Tony Reiman

Kathrin Tyryshkin

Wei Xu

Jan Delabie

Tony Reiman

Ralph Meyer

Christian Steidl

Sameh Basta